Michael L. Bernard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael L. Bernard has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Glenn M. Polin
Ochsner Medical Center, New Orleans, LA, USA
2 shared publicationsPaul A. Rogers
Ochsner Medical Center, New Orleans, LA, USA
2 shared publicationsSammy Khatib
Ochsner Medical Center, New Orleans, LA, USA
2 shared publicationsA. Elise Hiltbold
Ochsner Medical Center, New Orleans, LA, USA
1 shared publicationAnn Speed
Sandia National Laboratories Albuquerque, New Mexico
1 shared publication- Barbara S. Chaparro
Embry-Riddle Aeronautical University, Department of Human Factors and Behavioral Neurobiology
1 shared publication
Latest Publications
- 1 May 2021
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 66, 80-85
The role of atrial fibrillation catheter ablation in patients with heart failure
- 1 May 2021
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 66, 80-85
The role of atrial fibrillation catheter ablation in patients with heart failure
- Open Access
- 8 January 2020
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 31 (3) , 607-611
Class 1C antiarrhythmic drugs in atrial fibrillation and coronary artery disease
Background: Class 1C antiarrhythmic drugs (AADs) are effective first‐line agents for atrial fibrillation (AF) treatment. However, these agents commonly are avoided in patients with known coronary artery disease (CAD), due to known increased risk in the postmyocardial infarction population. Whether 1C AADs are safe in patients with CAD but without clinical ischemia or infarct is unknown. Reduced coronary flow capacity (CFC) on positron emission tomography (PET) reliably identifies myocardial regions supplied by vessels with CAD causing flow limitation.Objective: To assess whether treatment with 1C AADs increases mortality in patients without known CAD but with CFC indicating significantly reduced coronary blood flow.Methods: In this pilot study, we compared patients with AF and left ventricular ejection fraction ≥50% who were treated with 1C AADs to age‐matched AF patients without 1C AAD treatment. No patient had clinically evident CAD (ie, reversible perfusion defect, known ≥70% epicardial lesion, percutaneous coronary intervention, coronary artery bypass grafting, or myocardial infarction). All patients had PET‐based quantification of stress myocardial blood flow and CFC. Death was assessed by clinical follow‐up and social security death index search.Results: A total of 78 patients with 1C AAD exposure were matched to 78 controls. Over a mean follow‐up of 2.0 years, the groups had similar survival (P = .54). Among patients with CFC indicating the presence of occult CAD (ie, reduced CFC involving ≥50% of myocardium), 1C‐treated patients had survival similar to (P = .44) those not treated with 1C agents.Conclusions: In a limited population of AF patients with preserved left ventricle function and PET‐CFC indicating occult CAD, treatment with 1C AADs appears not to increase mortality. A larger study would be required to confidently assess the safety of these drugs in this context.
- 8 January 2020
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 31 (3) , 607-611
Open AccessClass 1C antiarrhythmic drugs in atrial fibrillation and coronary artery disease
Background: Class 1C antiarrhythmic drugs (AADs) are effective first‐line agents for atrial fibrillation (AF) treatment. However, these agents commonly are avoided in patients with known coronary artery disease (CAD), due to known increased risk in the postmyocardial infarction population. Whether 1C AADs are safe in patients with CAD but without clinical ischemia or infarct is unknown. Reduced coronary flow capacity (CFC) on positron emission tomography (PET) reliably identifies myocardial regions supplied by vessels with CAD causing flow limitation.Objective: To assess whether treatment with 1C AADs increases mortality in patients without known CAD but with CFC indicating significantly reduced coronary blood flow.Methods: In this pilot study, we compared patients with AF and left ventricular ejection fraction ≥50% who were treated with 1C AADs to age‐matched AF patients without 1C AAD treatment. No patient had clinically evident CAD (ie, reversible perfusion defect, known ≥70% epicardial lesion, percutaneous coronary intervention, coronary artery bypass grafting, or myocardial infarction). All patients had PET‐based quantification of stress myocardial blood flow and CFC. Death was assessed by clinical follow‐up and social security death index search.Results: A total of 78 patients with 1C AAD exposure were matched to 78 controls. Over a mean follow‐up of 2.0 years, the groups had similar survival (P = .54). Among patients with CFC indicating the presence of occult CAD (ie, reduced CFC involving ≥50% of myocardium), 1C‐treated patients had survival similar to (P = .44) those not treated with 1C agents.Conclusions: In a limited population of AF patients with preserved left ventricle function and PET‐CFC indicating occult CAD, treatment with 1C AADs appears not to increase mortality. A larger study would be required to confidently assess the safety of these drugs in this context.
- Open Access
- 16 December 2019
- Published by Ochsner Journal in Ochsner Journal
- Vol. 19 (4) , 401-404
Refractory Ventricular Tachycardia From Coronary Vasospasm During Pregnancy
Background: Coronary vasospasm leading to variant angina is uncommon, and the condition is rare in pregnant patients. Many physiologic changes occur during pregnancy, but how these changes affect the spasticity of coronary arteries in patients predisposed to vasospasm is unknown. Vasospasm causing unstable arrhythmia from multiple foci can be difficult to treat. Case Report: A 22-year-old gravida 1 para 0 female at 17 weeks’ gestation with twins presented with chest pain refractory to sublingual nitroglycerin, ST segment elevation on electrocardiogram, and subsequent ventricular tachycardia requiring a shock by her implantable cardioverter defibrillator (ICD). The patient had a history of coronary vasospasm with ventricular arrhythmia that required placement of the ICD 5 years prior. Because of refractory symptoms, she required prolonged admission in the intensive care unit with high-dose intravenous nitroglycerin, calcium channel blockers, benzodiazepines, beta blockers, chemical sympathectomy, and intubation and sedation. Despite these measures, the patient continued to have vasospasm and ventricular tachycardia, so cesarean delivery and tubal ligation were performed. After delivery, she was rapidly weaned from all invasive treatment modalities and was discharged on oral nitrates and calcium channel blockers. Conclusion: To our knowledge, this case is the first report of severe drug-refractory vasospastic angina triggered by pregnancy. The hormonal and nervous system changes that occur during pregnancy appear to be a trigger for vasospasm, further highlighted by the quick resolution of the patient9s symptoms postdelivery. A multidisciplinary approach for treatment of both mother and baby was necessary. Our case provides a cautionary tale that patients with refractory vasospastic angina may want to pursue definitive contraception.
- 16 December 2019
- Published by Ochsner Journal in Ochsner Journal
- Vol. 19 (4) , 401-404
Open AccessRefractory Ventricular Tachycardia From Coronary Vasospasm During Pregnancy
Background: Coronary vasospasm leading to variant angina is uncommon, and the condition is rare in pregnant patients. Many physiologic changes occur during pregnancy, but how these changes affect the spasticity of coronary arteries in patients predisposed to vasospasm is unknown. Vasospasm causing unstable arrhythmia from multiple foci can be difficult to treat. Case Report: A 22-year-old gravida 1 para 0 female at 17 weeks’ gestation with twins presented with chest pain refractory to sublingual nitroglycerin, ST segment elevation on electrocardiogram, and subsequent ventricular tachycardia requiring a shock by her implantable cardioverter defibrillator (ICD). The patient had a history of coronary vasospasm with ventricular arrhythmia that required placement of the ICD 5 years prior. Because of refractory symptoms, she required prolonged admission in the intensive care unit with high-dose intravenous nitroglycerin, calcium channel blockers, benzodiazepines, beta blockers, chemical sympathectomy, and intubation and sedation. Despite these measures, the patient continued to have vasospasm and ventricular tachycardia, so cesarean delivery and tubal ligation were performed. After delivery, she was rapidly weaned from all invasive treatment modalities and was discharged on oral nitrates and calcium channel blockers. Conclusion: To our knowledge, this case is the first report of severe drug-refractory vasospastic angina triggered by pregnancy. The hormonal and nervous system changes that occur during pregnancy appear to be a trigger for vasospasm, further highlighted by the quick resolution of the patient9s symptoms postdelivery. A multidisciplinary approach for treatment of both mother and baby was necessary. Our case provides a cautionary tale that patients with refractory vasospastic angina may want to pursue definitive contraception.
- 1 December 2019
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 94 (12) , 2381-2382
Atrial Fibrillation and Multimorbidity
- 1 December 2019
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 94 (12) , 2381-2382
Atrial Fibrillation and Multimorbidity
- Open Access
- 2 July 2016
- Published by Springer Nature
- p. 307-319
Examining the, Ideological, Sociopolitical, and Contextual Factors Underlying the Appeal of Extremism
- 2 July 2016
- Published by Springer Nature
- p. 307-319
Open AccessExamining the, Ideological, Sociopolitical, and Contextual Factors Underlying the Appeal of Extremism
- 1 January 2016
- Vol. 16 (3) , 238-42
Pacing Without Wires: Leadless Cardiac Pacing.
Worldwide, more than 700,000 pacemakers are implanted annually with more than 250,000 implanted in the United States. Since the first fully transvenous pacemaker implantations in the early 1960s, great technologic advances have been made in pacing systems. However, the combination of subcutaneous pulse generators and transvenous pacing leads has remained constant for more than 50 years. Leadless pacing systems offer an alternative to traditional pacing systems by eliminating the need for permanent transvenous leads while providing therapy for patients with bradyarrhythmias. We discuss the 2 leadless cardiac pacemakers (LCPs), the Nanostim Leadless Pacemaker and Micra Transcatheter Pacing System, and the 1 ultrasound-powered device, the WiCS-LV, that have been studied in humans. Currently LCPs are restricted to single-chamber pacing, specifically, ventricular pacing. Dual-chamber pacing and multichamber pacing with leadless systems have yet to be studied. LCPs represent the greatest advancement in bradycardia therapy since the first transvenous pacemaker implantation more than 50 years ago. Initial studies of both the Nanostim and Micra LCPs show favorable efficacy and safety results compared to transvenous pacemakers. Pending US Food and Drug Administration approval, these devices will transform our ability to provide pacing for patients with bradyarrhythmias. Future developments may allow for completely leadless single-chamber and multichamber pacing, ushering in an era of pacing without wires.
- 1 January 2016
- Vol. 16 (3) , 238-42
Pacing Without Wires: Leadless Cardiac Pacing.
Worldwide, more than 700,000 pacemakers are implanted annually with more than 250,000 implanted in the United States. Since the first fully transvenous pacemaker implantations in the early 1960s, great technologic advances have been made in pacing systems. However, the combination of subcutaneous pulse generators and transvenous pacing leads has remained constant for more than 50 years. Leadless pacing systems offer an alternative to traditional pacing systems by eliminating the need for permanent transvenous leads while providing therapy for patients with bradyarrhythmias. We discuss the 2 leadless cardiac pacemakers (LCPs), the Nanostim Leadless Pacemaker and Micra Transcatheter Pacing System, and the 1 ultrasound-powered device, the WiCS-LV, that have been studied in humans. Currently LCPs are restricted to single-chamber pacing, specifically, ventricular pacing. Dual-chamber pacing and multichamber pacing with leadless systems have yet to be studied. LCPs represent the greatest advancement in bradycardia therapy since the first transvenous pacemaker implantation more than 50 years ago. Initial studies of both the Nanostim and Micra LCPs show favorable efficacy and safety results compared to transvenous pacemakers. Pending US Food and Drug Administration approval, these devices will transform our ability to provide pacing for patients with bradyarrhythmias. Future developments may allow for completely leadless single-chamber and multichamber pacing, ushering in an era of pacing without wires.
- Open Access
- 1 January 2009
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 5, 733-737
Memory in Silico: Building a Neuromimetic Episodic Cognitive Model
We propose a neurologically plausible computational architecture to model human episodic memory and recall based on cortical-hippocampal structure and function. The model design is inspired by neuroscience findings and categorical neural semantic theory. Fuzzy Adaptive Resonance Theory (ART) and temporal integration are used to form episodic representations. Supported by the mathematical formalism of category theory, we theorize that correctly forming and manipulating episodic representations of sensory inputs, we can model elements of cognitive behavior. We demonstrate the architecturepsilas function by comparison to human experiments in an episodic memory task.
- 1 January 2009
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 5, 733-737
Open AccessMemory in Silico: Building a Neuromimetic Episodic Cognitive Model
We propose a neurologically plausible computational architecture to model human episodic memory and recall based on cortical-hippocampal structure and function. The model design is inspired by neuroscience findings and categorical neural semantic theory. Fuzzy Adaptive Resonance Theory (ART) and temporal integration are used to form episodic representations. Supported by the mathematical formalism of category theory, we theorize that correctly forming and manipulating episodic representations of sensory inputs, we can model elements of cognitive behavior. We demonstrate the architecturepsilas function by comparison to human experiments in an episodic memory task.
- 1 October 2003
- Published by SAGE Publications in Proceedings of the Human Factors and Ergonomics Society Annual Meeting
- Vol. 47 (3) , 302-306
Using Psychologically Plausible Operator Cognitive Models to Enhance Operator Performance
Research by Sandia National Laboratories (SNL) is currently being conducted that seeks to embody human-like cognitive capacities in machines by transforming the human-machine interaction so that it more closely resembles a human-to-human interaction. This document reports on the initial phase of research and development by SNL in creating a capability whereby a machine-based cognitive model provides a real-time awareness of the cognitive state of an operator. In the capability referred to as “Discrepancy Detection,” the machine uses an operator's cognitive model to monitor its own state and when there is evidence of a discrepancy between the actual state of the machine and the operator's perceptions concerning the state of the machine, a discrepancy may be signaled. The current project offers successful evidence that a machine may accurately infer an operator's interpretation of situations based on an individualized cognitive model of the operator.
- 1 October 2003
- Published by SAGE Publications in Proceedings of the Human Factors and Ergonomics Society Annual Meeting
- Vol. 47 (3) , 302-306
Using Psychologically Plausible Operator Cognitive Models to Enhance Operator Performance
Research by Sandia National Laboratories (SNL) is currently being conducted that seeks to embody human-like cognitive capacities in machines by transforming the human-machine interaction so that it more closely resembles a human-to-human interaction. This document reports on the initial phase of research and development by SNL in creating a capability whereby a machine-based cognitive model provides a real-time awareness of the cognitive state of an operator. In the capability referred to as “Discrepancy Detection,” the machine uses an operator's cognitive model to monitor its own state and when there is evidence of a discrepancy between the actual state of the machine and the operator's perceptions concerning the state of the machine, a discrepancy may be signaled. The current project offers successful evidence that a machine may accurately infer an operator's interpretation of situations based on an individualized cognitive model of the operator.
- 1 October 2001
- Published by SAGE Publications in Proceedings of the Human Factors and Ergonomics Society Annual Meeting
- Vol. 45 (6) , 637-639
Examining Automatic Text Presentation for Small Screens
This exploratory study compared three types of automatic text presentation for small screen interfaces—rapid serial visual presentation (RSVP), three lines, and ten-lines of text—at fast, medium and slow speeds for differences in reading comprehension, satisfaction, and preference. The results revealed a significant main effect of presentation speed, favoring the slowest speed. A marginal main effect of presentation method was also found, favoring RSVP and the ten-lines of text presentation. The readers were equally satisfied with all three methods of presentation.
- 1 October 2001
- Published by SAGE Publications in Proceedings of the Human Factors and Ergonomics Society Annual Meeting
- Vol. 45 (6) , 637-639
Examining Automatic Text Presentation for Small Screens
This exploratory study compared three types of automatic text presentation for small screen interfaces—rapid serial visual presentation (RSVP), three lines, and ten-lines of text—at fast, medium and slow speeds for differences in reading comprehension, satisfaction, and preference. The results revealed a significant main effect of presentation speed, favoring the slowest speed. A marginal main effect of presentation method was also found, favoring RSVP and the ten-lines of text presentation. The readers were equally satisfied with all three methods of presentation.